期刊
BLOOD
卷 136, 期 6, 页码 657-668出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020006075
关键词
-
类别
资金
- Incyte Corporation
- Novartis Pharmaceuticals Corporation
- National Institutes of Health, National Institute of Allergy and Infectious Diseases
- Histiocytosis Association of America
- American Lebanese Syrian Associated Charities
- Buster Posey Family Pediatric Cancer Pilot Award
- Campini Family Foundation
- Pepp Family Foundation
- St. Baldrick's Innovation Award
- Genentech Foundation Research Fellowship
- National Institutes of Health Medical Scientist Training Program [T32GM007618]
- University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center National Institutes of Health grant [P30CA082103]
Cytokine storm syndromes (CSS) are severe hyperinflammatory conditions characterized by excessive immune system activation leading to organ damage and death. Hemopha-gocytic lymphohistiocytosis (HLH), a disease often associated with inherited defects in cell -mediated cytotoxicity, serves as a prototypical CSS for which the 5-year survival is only 60%. Frontline therapy for HLH consists of the glucocorticoid dexamethasone (DEX) and the chemotherapeutic agent etoposide. Many patients, however, are refractory to this treatment or relapse after an initial response. Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease. We recently reported that cytokine-induced JAK/STAT signaling mediates DEX resistance in T cell acute lym-phoblastic leukemia (T-ALL) cells, and that this could be effectively reversed by RUX. On the basis of these findings, we hypothesized that cytokine-mediated JAK/STAT signaling might similarly contribute to DEX resistance in HLH, and that RUX treatment would overcome this phenomenon. Using ex vivo assays, a murine model of HLH, and primary patient samples, we demonstrate that the hypercytokinemia of HLH reduces the apoptotic potential of CD8 T cells leading to relative DEX resistance. Upon exposure to RUX, this apoptotic potential is restored, thereby sensitizing CD8 T cells to DEX-induced apoptosis in vitro and significantly reducing tissue immunopathology and HLH disease manifestations in vivo. Our findings provide rationale for combining DEX and RUX to enhance the lymphotoxic effects of DEX and thus improve the outcomes for patients with HLH and related CSS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据